OncoMatch/Clinical Trials/NCT02584244
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Is NCT02584244 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including LUM015 and LUM 2.6 Imaging Device for colorectal cancer.
Treatment: LUM015 · LUM 2.6 Imaging Device — The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Pancreatic Cancer
Esophageal Carcinoma
Gastric Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational drug
Subjects who have taken an investigational drug within 30 days of enrollment
Lab requirements
Blood counts
Leukocytes >= 3,000/mcL; Absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL
Kidney function
Creatinine within normal institutional limits or creatinine clearance >= 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
Liver function
total bilirubin within normal institutional limits (except in cases of malignant biliary obstruction); AST (SGOT)/ALT (SGPT) <= 2.5 X institutional upper limit of normal (<= 5 x ULN in cases of malignant biliary obstruction)
Cardiac function
QTc interval <= 480ms
Subjects must have normal organ and marrow function as defined below: Leukocytes >= 3,000/mcL; Absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL; total bilirubin within normal institutional limits (except in cases of malignant biliary obstruction); AST (SGOT)/ALT (SGPT) <= 2.5 X institutional upper limit of normal (<= 5 x ULN in cases of malignant biliary obstruction); Creatinine within normal institutional limits or creatinine clearance >= 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal. Subjects with QTc interval > 480ms [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify